Actinium Pharmaceuticals (ATNM) Operating Expenses (2010 - 2026)
Actinium Pharmaceuticals (ATNM) posted quarterly Operating Expenses of $5.9 million for Q1 2026, down 64.52% year-over-year from $16.6 million in Q1 2025, and down 7.97% quarter-over-quarter from $6.4 million in Q4 2025.
Actinium Pharmaceuticals (ATNM) Operating Expenses (2010 - 2026) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Operating Expenses for 17 consecutive years, with $5.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses fell 64.52% year-over-year to $5.9 million; the TTM figure through Mar 2026 stood at $25.6 million (down 47.92% YoY), while the FY2025 annual figure was $36.3 million, down 13.73% from the prior year.
- Operating Expenses fell to $5.9 million in Q1 2026 per ATNM's latest filing, from $6.4 million in the prior quarter.
- Across five years, Operating Expenses topped out at $16.6 million in Q1 2025 and bottomed at $5.8 million in Q3 2025.
- Historically, Operating Expenses has averaged $10.1 million across 5 years, with a median of $9.8 million in 2022.
- Annual changes were most pronounced in 2023 — Operating Expenses jumped 98.13% — and 2026, when it plunged 64.52%.
- Actinium Pharmaceuticals' Operating Expenses stood at $11.3 million in 2022, then decreased by 7.68% to $10.4 million in 2023, then slipped by 28.0% to $7.5 million in 2024, then declined by 14.54% to $6.4 million in 2025, then slipped by 7.97% to $5.9 million in 2026.
- Business Quant data shows ATNM's Operating Expenses at $5.9 million in Q1 2026, $6.4 million in Q4 2025, and $5.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.93 Bn | 131.08 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 86.11 Bn | 78.11 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 65.43 Bn | 60.25 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 56.09 Bn | 50.96 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 42.13 Bn | 37.03 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.49 Bn | 26.32 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 541.02 Mn |
| 10 | Actinium Pharmaceuticals | 34.85 Mn | 34.85 Mn | - | 7.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.44 Mn |
| Mar 31, 2026 | 5.90 Mn |
| Dec 31, 2025 | 6.41 Mn |
| Sep 30, 2025 | 5.78 Mn |
| Jun 30, 2025 | 7.50 Mn |
| Mar 31, 2025 | 16.64 Mn |
| Dec 31, 2024 | 7.51 Mn |
| Sep 30, 2024 | 12.60 Mn |
| Jun 30, 2024 | 12.42 Mn |
| Mar 31, 2024 | 9.60 Mn |
| Dec 31, 2023 | 10.42 Mn |
| Sep 30, 2023 | 14.35 Mn |
| Jun 30, 2023 | 15.64 Mn |
| Mar 31, 2023 | 11.58 Mn |
| Dec 31, 2022 | 11.29 Mn |
| Sep 30, 2022 | 9.84 Mn |
| Jun 30, 2022 | 7.90 Mn |
| Mar 31, 2022 | 6.10 Mn |
| Dec 31, 2021 | 8.07 Mn |
| Sep 30, 2021 | 6.70 Mn |